Neurology

Myelodysplastic Syndromes

Questions discussed in this category

How do you manage high-risk MDS IB2 patients on HMA and venetoclax who develop an acute stroke requiring antiplatelet therapy?

1 Answer available

When patients develop headaches from luspatercept, do they tend to improve over time?

1 Answer available

Papers discussed in this category

Blood Adv,

Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure.

Blood cancer journal, 2025 Apr 17

Reduced venetoclax exposure to 7 days vs standard exposure with hypomethylating agents in newly diagnosed AML patients.

Related Topics in Neurology